ALCAM and cancer: While the regulation of alternative splicing has not been studied for ALCAM specifically, aberrations in alternative splicing in cancer can be attributed to several factors such as genetic abnormalities in spliceosome machinery or, more commonly, to dysregulation of expression and localization of trans-acting splicing factors52.